Cardiac Regenerative Therapy
VentriNova, Inc., New York, United States
Harnessing the molecular pathway that regulates cardiac muscle cell division in the embryonic heart, a pathway that becomes dormant after birth, VentriNova has developed a treatment to regenerate cardiac tissue after a heart attack. This is the only existing technology that actually creates NEW cardiac cells.
Primary Application Area: Biotech & Biological Sciences
Technology Development Status: Prototype
Technology Readiness Level: TRL 3
FIGURES OF MERIT
Value Proposition: VentriNova has developed a groundbreaking treatment, attested to by the fact that the proof of concept studies are in press at Science Translational Medicine, publication date 2/26/14. This therapy is truly disruptive and has the potential to be a transformative advance in the treatment of heart disease.
Organization Type: Early-stage Startup (Seed)
Showcase Booth #: 858
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: VentriNova, Inc. was awarded a Phase I STTR in 2009 which obtained the highest score nationally over a 5-yr period for all grants received at the National Heart, Lung, and Blood Institute of the NIH. This funding has been used to complete proof-of-concept testing in a large animal model of myocardial infarction and study the underlying mechanisms of cyclin A2-mediated cardiac repair.
Primary Sources of Funding: Venture Capital, Personal Savings, Federal Grant
Looking for: Both Funding and Development Partners